ArticleThe Journal of physiology2005
Signal transduction pathway for the substance P-induced inhibition of rat Kir3 (GIRK) channel.
Article in The Journal of physiology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 23 citations in OpenAlex.
- Article
- Gi/o-coupled muscarinic receptors co-localize with GIRK channel for efficient channel activation.PloS one · 2018Article
- The pharmacology of neurokinin receptors in addiction: prospects for therapy.Substance abuse and rehabilitation · 2015Review
- Neuropeptide transmission in brain circuits.Neuron · 2012Review
- Direct inhibition of the cold-activated TRPM8 ion channel by Gαq.Nature cell biology · 2012Article
- Diverse roles of G-protein coupled receptors in the regulation of neurohypophyseal hormone secretion.Journal of neuroendocrinology · 2012Review
- Emerging role(s) of G-protein alpha-subunits in the gating of GIRKs.The Journal of physiology · 2009Article
- Morphological and physiological properties of serotonergic neurons in dissociated cultures from the postnatal rat dorsal raphe nucleus.Journal of neuroscience methods · 2008Article
- Modulation of the heteromeric Kir4.1-Kir5.1 channel by multiple neurotransmitters via Galphaq-coupled receptors.Journal of cellular physiology · 2008Article
- Crystal structure of a Kir3.1-prokaryotic Kir channel chimera.The EMBO journal · 2007Article
- Neurokinins enhance excitability in capsaicin-responsive DRG neurons.Experimental neurology · 2007Article
- Inhibition of a background potassium channel by Gq protein alpha-subunits.Proceedings of the National Academy of Sciences of the United States of America · 2006Article
Corrections and comments
- Erratum issued
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
Certain transmitters inhibit Kir3 (GIRK) channels, resulting in neuronal excitation. We analysed signalling mechanisms for substance P (SP)-induced Kir3 inhibition in relation to the role of phosphatidylinositol 4,5-bisphosphate (PIP(2)). SP rapidly - with a half-time of approximately 10 s with intracellular GTPgammaS and approximately 14 s with intracellular GTP - inhibits a robustly activated Kir3.1/Kir3.2 current. A mutant Kir3 channel, Kir3.1(M223L)/Kir3.2(I234L), which has a stronger binding to PIP(2) than does the wild type Kir3.1/Kir3.2, is inhibited by SP as rapidly as the wild type Kir3.1/Kir3.2. This result contradicts the idea that Kir3 inhibition originates from the depletion of PIP(2). A Kir2.1 (IRK1) mutant, Kir2.1(R218Q), despite having a weaker binding to PIP(2) than wild type Kir3.1/Kir3.2, shows a SP-induced inhibition slower than the wild type Kir3.1/Kir3.2 channel, again conflicting with the PIP(2) theory of channel inhibition. Co-immunoprecipitation reveals that Galpha(q) binds with Kir3.2, but not with Kir2.2 or Kir2.1. These functional results and co-immunoprecipitation data suggest that G(q) activation rapidly inhibits Kir3 (but not Kir2), possibly by direct binding of Galpha(q) to the channel.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.